一项单臂临床试验:非激素透明质酸阴道保湿剂对子宫内膜癌生存者的疗效
该单臂、前瞻性、纵向试验纳入43例接受全子宫切除及术后放疗的无病子宫内膜癌生存者,使用透明质酸阴道凝胶后外阴阴道症状评分及临床检查指标显著改善,阴道pH严重升高比例从30%降至19%但未达统计学显著。
要点
- 透明质酸凝胶可改善子宫内膜癌生存者的外阴阴道症状及性功能。
- 自然绝经女性推荐每周使用1-2次透明质酸凝胶。
- 癌症生存者每周3-5次方案对症状缓解似乎更有效。
核心结论
- 透明质酸凝胶改善了子宫内膜癌生存者的外阴阴道健康及性功能,在感知症状和临床检查结局方面均有体现。
- 自然绝经女性推荐每周使用透明质酸凝胶1-2次;对癌症生存者,每周3-5次方案对症状缓解似乎更有效。
研究设计与样本
- 单臂、前瞻性、纵向试验,纳入43例接受全子宫切除及术后放疗的无病子宫内膜癌生存者。
- 参与者前2周每日使用透明质酸凝胶,之后每周3次至第12-14周;无应答者剂量增至每周5次。
- 在4个时间点(基线T1;4-6周T2;12-14周T3;22-24周T4)通过临床评估、阴道评估量表(VAS)、外阴评估量表(VuAS)、女性性功能指数(FSFI)及绝经症状清单(MSCL)进行评估。
主要发现
- 43例患者平均年龄59岁(范围38-78);54%(23/43)有伴侣;49%(21/43)有性活动。
- VAS、VuAS、MSCL及性活动问卷(SAQ)评分从基线至各评估点均显著改善(所有p < .002)。
- FSFI总平均分从T1至T2显著升高(p < .05),从T1至T4显著升高(p < .03)。
- T1时41%(16/39)对未来性活动感到自信,T4时为68%(17/25)(p = .096)。
- 阴道pH严重升高(>6.5)的比例从T1的30%(13/43)降至T4的19%(5/26)(p = .41)。
临床怎么用
- 作者建议自然绝经女性每周使用透明质酸凝胶1-2次。
- 作者认为对癌症生存者每周3-5次方案对症状缓解似乎更有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy of non-hormonal, hyaluronic acid (HLA)-based vaginal gel in improving vulvovaginal estrogen-deprivation symptoms in women with a history of endometrial cancer. METHODS: For this single-arm, prospective, longitudinal trial, we enrolled disease-free women with a history of endometrial cancer who underwent surgery (total hysterectomy) and postoperative radiation. Participants used HLA daily for the first 2 weeks, and then 3×/week until weeks 12-14; dosage was then increased to 5×/week for non-responders. Vulvovaginal symptoms and pH were assessed at 4 time points (baseline [T1]; 4-6 weeks [T2]; 12-14 weeks [T3]; 22-24 weeks [T4]) with clinical evaluation, the Vaginal Assessment Scale (VAS), Vulvar Assessment Scale (VuAS), Female Sexual Function Index (FSFI), and Menopausal Symptom Checklist (MSCL). RESULTS: Of 43 patients, mean age was 59 years (range, 38-78); 54% (23/43) were partnered; and 49% (21/43) were sexually active. VAS, VuAS, MSCL, and SAQ (Sexual Activity Questionnaire) scores significantly improved from baseline to each assessment point (all p < .002). FSFI total mean scores significantly increased from T1 to T2 (p < .05) and from T1 to T4 (p < .03). At T1, 41% (16/39) felt confident about future sexual activity compared to 68% (17/25) at T4 (p = .096). Severely elevated vaginal pH (>6.5) decreased from 30% (13/43) at T1 to 19% (5/26) at T4 (p = .41). CONCLUSION: The HLA-based gel improved vulvovaginal health and sexual function of endometrial cancer survivors in perceived symptoms and clinical exam outcomes. HLA administration 1-2×/week is recommended for women in natural menopause; a 3-5×/week schedule appears more effective for symptom relief in cancer survivors.
引用
- Carter J, Goldfarb S, Baser RE, et al. A single-arm clinical trial investigating the effectiveness of a non-hormonal, hyaluronic acid-based vaginal moisturizer in endometrial cancer survivors. Gynecol Oncol. 2020. PMID: 32522420. doi:10.1016/j.ygyno.2020.05.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。